Current Report Filing (8-k)
15 March 2019 - 8:31AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 14, 2019 (March 12, 2019)
LUCKWEL
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
333-187874
|
|
46-1660653
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
303
Wyman St Suite 300, Waltham
|
|
MA
02451
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, include area code
+1(781)728 0007
100
S. Saunders Road, Suite 150, Lake Forest, IL 60045
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
1.01 Entry into a Material Definitive Agreement
On
March 12, 2019, Luckwel Pharmaceuticals Inc. (the “Company”) entered into an online office agreement with Regus Management
Group, LLC (the “Agreement”), pursuant to which the Company leased an office space located at 303 Wyman St Suite 300,
Waltham, MA 02451. The lease under the Agreement will start on March 14, 2019 on a month-to-month basis for which the Company
pays a monthly fee of $500.
This
description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the form of Agreement,
a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K.
Item
9.01 Financial Statements and Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
LUCKWEL
PHARMACEUTICALS INC.
|
|
|
|
Date:
March 14, 2019
|
|
/s/
Kingrich Lee
|
|
Name:
|
Kingrich
Lee
|
|
Title:
|
Chief
Executive Officer and Chief Financial Officer
|
Luckwel Pharmaceuticals (GM) (USOTC:LWEL)
Historical Stock Chart
From May 2024 to Jun 2024
Luckwel Pharmaceuticals (GM) (USOTC:LWEL)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Luckwel Pharmaceuticals Inc (GM) (OTCMarkets): 0 recent articles
More Luckwel Pharmaceuticals Inc. News Articles